Cystic fibrosis gene mutations

• US 8,460,871 B2
• Filed: 11/07/2011
• Issued: 06/11/2013
• Est. Priority Date: 03/05/2004
• Status: Expired due to Fees

• Current Assignee: Quest Diagnostics Investments Incorporated (Quest Diagnostics Incorporated)
• Original Assignee: Quest Diagnostics Investments Incorporated (Quest Diagnostics Incorporated)
• Inventors: McGinniss, Matthew J., Buller, Arlene M., Quan, Franklin, Peng, Mei, Sun, Weimin
• Primary Examiner(s): GOLDBERG, JEANINE ANNE
• Application Number:
  US13/290,814
• Publication Number:
  US 20120082982A1
• Time in Patent Office: 582 Days
• Field of Search: None
• US Class Current: 435/6.1
• CPC Class Codes: C12Q 1/6883 for diseases caused by alterations of genetic material
• CPC Class Codes: C12Q 2600/156 Polymorphic or mutational markers
• CPC Class Codes: Y10T 436/143333 Saccharide [e.g., DNA, etc.]

Abstract

The present invention provides novel mutations of the CFTR gene related to cystic fibrosis or to conditions associated with cystic fibrosis. Also provided are probes for detecting the mutant sequences. Methods of identifying if an individual has a genotype containing one or more mutations in the CFTR gene are further provided.

Claims

1. A method of determining the cystic fibrosis status of a human comprising:

(a) determining the presence of a c.1509_—

1510delinsT mutation in one or both alleles of the cystic fibrosis transmembrane regulatory (CFTR) gene in a nucleic acid sample obtained from the human wherein the determining comprises hybridizing with a detectably labeled probe comprising the mutant CFTR sequence, and

(b) identifying the human;

(i) as having cystic fibrosis or being predisposed to cystic fibrosis when the human is homozygous for the c.1509_—

1510delinsT mutation in the CFTR gene, or

(ii) as being a cystic fibrosis carrier when the human is heterozygous for the c.1509_—

1510delinsT mutation in the CFTR gene, or

(iii) as having no predisposition or carrier status caused by the c.1509_—

1510delinsT mutation when the c.1509_—

1510delinsT mutation is not present in either allele of the CFTR gene.

2. The method of claim 1, wherein genomic DNA is tested for the presence of said mutation.

3. The method of claim 1, wherein a cDNA copy of the CFTR coding sequence is tested for the presence of said mutation.

4. The method of claim 1, wherein the presence of said mutation is additionally determined by nucleic acid sequencing.

5. The method of claim 1, wherein the presence of said mutation is additionally determined by restriction fragment length polymorphism analysis following treatment of CFTR gene sequence with at least one endonuclease restriction enzyme.

6. The method of claim 1, wherein the presence of said mutation is additionally determined by allele specific amplification.

7. The method of claim 1, wherein the presence of said mutation is additionally determined by primer extension.

8. The method of claim 1, wherein the presence of said mutation is additionally determined by oligonucleotide ligation.

9. A method of determining if a human is predisposed to cystic fibrosis comprising:

(a) determining the presence of a c.1509_—

1510delinsT mutation in one or both alleles of the cystic fibrosis transmembrane regulatory (CFTR) gene in a nucleic acid sample obtained from the human wherein the determining comprises hybridizing with a detectably labeled probe comprising the mutant CFTR sequence, and

(b) identifying said human;

(i) as being predisposed to cystic fibrosis when the human is homozygous for the c.1509_—

1510delinsT mutation in the CFTR gene, or

(ii) as having no predisposition to cystic fibrosis when the human is heterozygous for the c.1509_—

1510delinsT mutation in the CFTR gene or when the c.1509_—

1510delinsT mutation is not present in either allele of the CFTR gene.

10. The method of claim 9, wherein genomic DNA is tested for the presence of said mutation.

11. The method of claim 9, wherein a cDNA copy of the CFTR coding sequence is tested for the presence of said mutation.

12. The method of claim 9, wherein the presence of said mutation is additionally determined by nucleic acid sequencing.

13. The method of claim 9, wherein the presence of said mutation is additionally determined by restriction fragment length polymorphism analysis following treatment of CFTR gene sequence with at least one endonuclease restriction enzyme.

14. The method of claim 9, wherein the presence of said mutation is additionally determined by allele specific amplification.

15. The method of claim 9, wherein the presence of said mutation is additionally determined by primer extension.

16. The method of claim 9, wherein the presence of said mutation is additionally determined by oligonucleotide ligation.

17. A method of identifying a human as having an increased likelihood of having an offspring afflicted with cystic fibrosis, comprising:

(a) determining the presence of the c.1509_—

1510delinsT mutation in one or both alleles of the CFTR gene in a nucleic acid sample obtained from the human wherein said determining comprises hybridizing with a detectably labeled probe comprising the mutant CFTR sequence, and

(b) identifying said human as having an increased likelihood of having an offspring afflicted with cystic fibrosis when said c.1509_—

1510delinsT mutation is present in at least one allele.

18. The method of claim 17, wherein genomic DNA is tested for the presence of said mutation.

19. The method of claim 17, wherein a cDNA copy of the CFTR coding sequence is tested for the presence of said mutation.

20. The method of claim 17, wherein the presence of said mutation is additionally determined by nucleic acid sequencing.

21. The method of claim 17, wherein the presence of said mutation is additionally determined by restriction fragment length polymorphism analysis following treatment of CFTR gene sequence with at least one endonuclease restriction enzyme.

22. The method of claim 17, wherein the presence of said mutation is additionally determined by allele specific amplification.

23. The method of claim 17, wherein the presence of said mutation is additionally determined by primer extension.

24. The method of claim 17, wherein the presence of said mutation is additionally determined by oligonucleotide ligation.

25. A method of determining the cystic fibrosis status of a human comprising:

(a) analyzing a nucleic acid sample from said human;

(b) detecting the presence of a c.1509_—

1510delinsT mutation in one or both alleles of the cystic fibrosis transmembrane regulatory (CFTR) gene in the nucleic acid sample obtained from said human, and

(c) identifying the human;

(i) as having cystic fibrosis or being predisposed to cystic fibrosis when the human is homozygous for the c.1509_—

1510delinsT mutation in the CFTR gene, thereby correlating the human with having cystic fibrosis;

or

(ii) as being a cystic fibrosis carrier when the human is heterozygous for the c.1509_—

1510delinsT mutation in the CFTR gene thereby correlating the human with having a predisposition for cystic fibrosis.

26. A method of determining if a human is predisposed to cystic fibrosis comprising:

(a) analyzing a nucleic acid sample from said human;

(b) detecting the presence of a c.1509_—

1510delinsT mutation in one or both alleles of the cystic fibrosis transmembrane regulatory (CFTR) gene in the nucleic acid sample obtained from said human, and

(c) identifying said human as;

(i) being predisposed to cystic fibrosis when the human is homozygous for the c.1509_—

1510delinsT mutation in the CFTR gene, or

(ii) having no predisposition to cystic fibrosis when the human is heterozygous for the c.1509_—

1510delinsT mutation in the CFTR gene.

27. A method of identifying a human as having an increased likelihood of having an offspring afflicted with cystic fibrosis, comprising:

(a) analyzing a nucleic acid sample from said human;

(b) detecting the presence of the c.1509_—

1510delinsT mutation in one or both alleles of the CFTR gene in the nucleic acid sample obtained from said human, and

(c) identifying said human as having an increased likelihood of having an offspring afflicted with cystic fibrosis when the c.1509_—

1510delinsT mutation is detected in at least one allele.